Benzinga | Jan 11, 2021 08:20AM EST

Resolution Bioscience Announces Companion Diagnostic Collaboration With Mirati Therapeutics

Resolution's liquid biopsy assay to help identify non-small cell lung cancer patients who may benefit from Mirati's investigational KRAS G12C inhibitor therapy

Resolution Bioscience, Inc. today announced a companion diagnostic agreement with Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical stage targeted oncology company. As part of the agreement, Resolution's ctDx(tm) liquid biopsy technology will be used to help identify non-small cell lung cancer (NSCLC) patients who may benefit from Mirati's investigational KRAS G12C inhibitor therapy. The fast and non-invasive assay was designed to detect actionable NSCLC mutations, such as KRAS G12C.

Cancers stemming from RAS mutations account for nearly a quarter of all human cancers and contribute to 1 million deaths per year worldwide. Among the RAS family of oncogenes, KRAS gene mutations are the most common, making up to 85% of all RAS mutations. Mirati's investigational drug candidate adagrasib (MRTX849) is an orally available small molecule that potently and selectively inhibits the G12C substitution mutation. The Resolution assay will be used to identify patients whose cancers are driven by this KRAS variant.

"We are excited to join forces with Mirati to address this large unmet medical need and to further drive adoption of our innovative liquid biopsy diagnostic tests," said Mark Li, CEO of Resolution Bioscience. "Our mission is to provide critical, actionable information to improve care and clinical outcomes for cancer patients worldwide."